tiprankstipranks
pc:everz

EVerZom

45, Rue des Saints-Pères Paris, Ile-de-France, FR
https://everzom.com/
EVerZom is a French biotechnology company specializing in the development of exosome-based therapies for regenerative medicine. The company is advancing a proprietary bioproduction platform that leverages mesenchymal stem cell-derived exosomes, aiming to address high unmet medical needs across multiple therapeutic areas, including inflammatory diseases, hepatology, and dermatology. EVerZom's flagship product, EVerGel™, is set to enter clinical trials for Crohn's disease-related perianal fistulas, showcasing the potential of exosomes as a novel therapeutic modality.

Leadership & Board

Current Number of Employees25
Current LinkedIn Followers6,940

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$10M
Total Amount Raised$10M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$10M
Latest Funding Amount$10M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation
Post-Money Valuation

Employee Trend

EVerZom had 25 employees as of September 7, 2026. The number of employees increased by 0 (0.00%) week-over-week.
25Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.

Social Trend

EVerZom had 6,940 followers as of September 7, 2026. The number of followers increased by 11 (0.16%) week-over-week.
6,940Latest Followers Count
11(0.16%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Oct 14, 2025
Investment
$10.00M

Investors

Similar Companies

A snapshot of private companies similar to EVerZom, helping you discover and navigate related company profiles.

Related News and Analysis